Galectin: Soars on data showing lead drug's potential in cancer treatment

Galectin Therapeutics

14/04/2021 11:19

** Drug developer's shares  GALT.O  rise 33% premarket and
are set to open at a more than 6-month high of $2.88; GALT is
among the top pct gainers across U.S. exchanges 
    ** With ~800,000 shares changing hands by 6:13 a.m. ET, GALT
is the 2nd most heavily traded U.S. stock
    ** Co says paper published in a medical journal shows using
co's lead drug candidate with Merck & Co's  MRK.N  cancer drug
Keytruda significantly enhances tumor response to immunotherapy
in patients with two types of cancer  urn:newsml:reuters.com:*:nGNX22pZHw
    ** Results were published from co's ongoing early-stage
study of drug, belapectin, in patients with an advanced type of
skin cancer, head and neck cancer
    ** Authors of paper note the combination was associated with
fewer immune-mediated adverse events than expected with Keytruda
alone - GALT
    ** Belapectin is being tested to treat various inflammatory,
fibrotic and malignant diseases
    ** GALT had fallen 3.4% YTD 
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))